AffiliationDepartment of Medicine, Sligo General Hospital, Republic of Ireland.
MeSHAntidepressive Agents, Second-Generation
Cost of Illness
MetadataShow full item record
CitationUpdate on smoking cessation therapies. 2009, 26 (4):369-82 Adv Ther
JournalAdvances in therapy
AbstractAs a reflection of an exponential increase in smoking rates throughout the world during the last century, the economic and human burden of mortality and morbidity related to smoking is now clearly defined. Smoking cessation is associated with health benefits for people of all ages. In this paper we provide a comprehensive review of current licensed pharmacological smoking cessation agents including efficacy and safety profiles, with comparisons of individual therapies available. Furthermore, we offer a prospective on the need for further testing of other agents including novel avenues of therapy.
- A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline.
- Authors: Johnson TS
- Issue date: 2010 Oct
- The truth about smoking cessation.
- Issue date: 2007 Oct
- Smoking cessation intervention: an evidence-based approach.
- Authors: Laniado-Laborín R
- Issue date: 2010 Mar
- Varenicline: a first-line treatment option for smoking cessation.
- Authors: Garrison GD, Dugan SE
- Issue date: 2009 Mar
- Cost-effectiveness of varenicline for smoking cessation.
- Authors: Keiding H
- Issue date: 2009 Jun